Videos

The associate vice president of research at National MS Society talked about proactive and early referral to rehabilitation services to effectively manage multiple sclerosis symptoms from the outset. [WATCH TIME: 4 minutes]

The pediatric neurologist at the University of California, Davis, provided perspective on some of the mechanistic links between sleep and neurodevelopmental disorders. [WATCH TIME: 3 minutes]

Sharon Cohen, MD, and Marwan Sabbagh, MD, share their final thoughts on Alzheimer's disease and offer advice on strategies to reduce the risk of developing AD and slow the progression of the disease for those already affected.

Key opinion leaders discuss the Alzheimer's disease pipeline and the numerous disease-modifying therapies under investigation.

The sleep medicine specialist at the University of California, San Francisco provided perspective on some of the innovative therapeutic strategies in development for patients with obstructive sleep apnea. [WATCH TIME: 5 minutes]

The assistant professor of neurology in the Perelman School of Medicine at University of Pennsylvania talked about her presentation at CMSC 2024 on the complex interactions of immune cells in multiple sclerosis. [WATCH TIME: 6 minutes]

The professor of neurology at Mayo Clinic talked about how MOG antibody-associated disease can be diagnosed through specific antibody tests, highlighting its distinct clinical and MRI features. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending June 1, 2024. [WATCH TIME: 4 minutes]

Host Jeffrey Wilken, PhD, chats with Marijean Buhse, PhD, RN, NP-C, MSCN; Amy Sullivan, PsyD, ABPP; and John DeLuca, PhD, ABPP, FACRM, FAPA, FAPS, FNAN, about the third day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.

The professor of psychiatry at the University of Toronto discussed the various medications for multiple sclerosis fatigue that have been tested but ultimately fail to outperform placebo. [WATCH TIME: 4 minutes]

The professor of neurology in the department of medicine, surgery, and neuroscience at the University of Siena, gave perspective on an analysis of the MAGNIFY-MS study, in which treatment with cladribine demonstrated impacts on CNS-related pathology in MS. [WATCH TIME: 4 minutes]

Host Jeffrey Wilken, PhD, chats with Fred Lublin, MD; Brian Hutchinson, PT, MSCS; and Robert Motl, PhD, about the second day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.

The clinical research director of the UCSF Multiple Sclerosis Center talked about results from clinical trials assessing BTK inhibitors in relapsing multiple sclerosis and the ongoing research to explore more effective treatments. [WATCH TIME: 5 minutes]

Host Jeffrey Wilken, PhD, chats with Robert Naismith, MD; Jiwon Oh, MD, PhD; and Anthony Traboulsee, MD, about the first day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.

The clinical research director of the UCSF Multiple Sclerosis Center discussed the early-onset progression in multiple sclerosis and emphasized the need for targeted therapies in this patient population. [WATCH TIME: 6 minutes]

Medical experts discuss the application of ApoE gene polymorphism and copy number data in managing Alzheimer's disease, highlighting its relevance for individuals with a family history of AD, and symptomatic patients.

Panelists review the use of CSF and blood-based biomarkers in Alzheimer's disease, discussing the role of tau as a marker of neuronal injury and its utility in staging the progression of Alzheimer's disease.

The director of research in the Jane and John Justin Neurosciences Center at Cook Children's Health Care System talked about ongoing research on biomarkers to enhance treatment and improve cognitive outcomes. [WATCH TIME: 6 minutes]

Neurology News Network. for the week ending May 25, 2024. [WATCH TIME: 4 minutes]

The lead neuroscientist and lead data scientist at Rune Labs talked about leveraging mobility data to monitor progression in patients with Parkinson disease. [WATCH TIME: 7 minutes]

The professor and chair of rehabilitation medicine at UT Health San Antonio talked about the newly published guidelines for the assessment and management of spasticity in patients with neurological conditions. [WATCH TIME: 5 minutes]

The vascular neurosurgeon and professor of neurological surgery at The Ohio State University Wexner Medical Center spoke about advancements in stroke treatment, including endovascular thrombectomy and new drug therapies, that aim to address unmet need in patients. [WATCH TIME: 5 minutes]

The chief medical officer of New England Center for Neurology and Headache talked about trends observed in the clinical practice with Daxxify, a long-acting botulinum toxin for patients with cervical dystonia. [WATCH TIME: 5 minutes]

Key opinion leaders emphasize the importance of neuroimaging in Alzheimer's disease, as it can rule out different diseases and diagnose microbleeds, while also discussing which biomarkers, histopathological features, and imaging characteristics are associated with different stages of the disease, exploring whether these tools can provide insights into the true onset of Alzheimer's disease.

Sharon Cohen, MD, and Marwan Sabbagh, MD, discuss the current understanding of tau as a marker of neuronal injury and its role in the pathophysiology of Alzheimer's disease, particularly focusing on the significance of phosphorylated tau and neurofibrillary tangles in the disease process.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, share perspectives on the future of MS care, the importance of vigilance in lab testing, and why patients may need reassurance about the potential for disease control with currently available therapies.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss the need for biomarkers that can help guide the optimal dosing for the use of anti-CD20 therapies in a precision fashion.

The associate professor of neurology at Harvard Medical School discussed how clinicians face the challenging decision with their patients in choosing between off-label and approved medications for NMOSD. [WATCH TIME: 4 minutes]

Neurology News Network. for the week ending May 18, 2024. [WATCH TIME: 4 minutes]

Drs Thorpy, Dogan, Doghramji, and Kushida share clinical pearls for primary care providers who are taking care of patients with narcolepsy.